Bioavailability of amlodipine besylate following oral administration as a tablet dispersed in applesauce

Journal of Clinical Pharmacology

Volumn 45, Issue 6, 2005, Pages 695-698

  Chung, Menger ^a   Garza, Dahlia ^a   Gaffney, Michael ^a   Glue, Paul ^a  

^a PFIZER INC   (United States)

Author keywords

Amlodipine; Applesauce; Bioavailability; Pharmacokinetic

Indexed keywords

AMLODIPINE BESYLATE;

ADULT; APPLE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; TABLET DISINTEGRATION;

ADMINISTRATION, ORAL; ADULT; AMLODIPINE; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; EXCIPIENTS; FEMALE; FRUIT; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; TABLETS;

EID: 18844395101     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005276203     Document Type: Article

References (15)

1. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755-1762.
2. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
3. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350:757-764.
4. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703-713.
5. Mallion JM, Genes N, Vaur L, et al. Blood pressure levels, risk factors and antihypertensive treatments: lessons from the SHEAF study. J Hum Hypertens. 2001;15:841-848.
6. Swales JD. Current clinical practice in hypertension: the EISBERG (Evaluation and Interventions for Systolic Blood pressure Elevation-Regional and Global) project. Am Heart J. 1999;138:231-237.
7. Cardinal H, Monfared AA, Dorais M, LeLorier J. A comparison between persistence to therapy in ALLHAT and in everyday clinical practice: a generalizability issue. Can J Cardiol. 2004;20:417-421.
8. Oliveria S. Adherence to goal attainment and hypertension guidelines in a clinical practice setting. Arch Intern Med. In press.
9. Runions S, Rodrigue N, White C. Practice on an acute stroke unit after implementation of a decision-making algorithm for dietary management of dysphagia. J Neurosci Nurs. 2004;36:200-207.
10. Ginsburg CM, McCracken GH Jr, Olsen K. Pharmacology of ketoconazole suspension in infants and children. Antimicrob Agents Chemother. 1983;23:787-789.
11. Bulges RA. Amlodipine: a once daily calcium antagonist. J Hum Hypertens. 1991;(5 suppl 1):49-54.
12. Eguchi K, Kario K, Hoshide Y, et al. Comparison of valsartan and amlodipine on ambulatory and morning blood pressure in hypertensive patients. Am J Hypertens. 2004;17:112-117.
13. Kario K, Shimada K. Differential effects of amlodipine on ambulatory blood pressure in elderly hypertensive patients with different nocturnal reductions in blood pressure. Am J Hypertens. 1997;10:261-268.
14. Food and Drug Administration. Guidance for Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies. Washington, DC: Department of Health and Human Services; 2002.
15. Kario K, Shimada K. Differential effects of amlodipine on ambulatory blood pressure in elderly hypertensive patients with different nocturnal reductions in blood pressure. Am J Hypertens. 1997;10:261-268.